文献速递心律失常

植入式除颤器用于遗传性心律失常的一级预防:一个令人震惊的选择?

Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?
PubMed 文献 · Eur Heart J · 2022-01-01

本文综述遗传性心律失常疾病患者心脏性猝死(SCD)的危险因素及植入式心律转复除颤器(ICD)植入指征。由于随机试验不可行,风险评估基于观察数据和专家共识。文章指出,目前存在一种日益增长且令人不安的趋势,即创建并使用半自动化系统(风险评分、风险计算器及部分指南)来主导治疗选择,其共同点是倾向于ICD植入,有时合理,有时不合理。这与基于临床判断、在评估最佳药物治疗保护后选择最佳治疗(包括ICD)的悠久方法形成对比。

要点

  • 遗传性心律失常疾病SCD危险因素精确性低于冠心病。
  • ICD植入决策基于观察数据和专家共识,随机试验不可行。
  • 半自动化风险评分系统倾向ICD植入,需警惕过度使用。

核心结论

  • 在遗传性心律失常疾病一级预防中,ICD植入决策应基于个体化临床判断和最佳药物治疗评估,而非依赖倾向ICD的半自动化系统。

研究设计与样本

  • 本文为综述,回顾遗传性心律失常疾病SCD危险因素和ICD植入指征及附加治疗。

主要发现

  • 遗传性心律失常疾病包括肥厚型心肌病、致心律失常性心肌病、长QT综合征、Brugada综合征、儿茶酚胺敏感性多形性室性心动过速和短QT综合征。
  • 与冠心病相比,遗传性心律失常疾病SCD危险因素不精确。
  • 随机研究通常不可行且可能不符合伦理,风险评估基于观察数据和专家共识。
  • 存在日益增长且令人不安的趋势,即创建并使用半自动化系统(风险评分、风险计算器及部分指南)主导治疗选择,倾向ICD植入。

临床怎么用

  • 临床决策应基于个体化临床判断,评估最佳药物治疗保护后选择最佳治疗选项(包括ICD)。
  • 警惕半自动化风险评分系统可能导致的ICD过度植入倾向。

局限性

  • 风险评估基于观察数据和专家共识,缺乏随机试验证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many previously unexplained life-threatening ventricular arrhythmias and sudden cardiac deaths (SCDs) in young individuals are now recognized to be genetic in nature and are ascribed to a growing number of distinct inherited arrhythmogenic diseases. These include hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (VT), and short QT syndrome. Because of their lower frequency compared to coronary disease, risk factors for SCD are not very precise in patients with inherited arrhythmogenic diseases. As randomized studies are generally non-feasible and may even be ethically unjustifiable, especially in the presence of effective therapies, the risk assessment of malignant arrhythmic events such as SCD, cardiac arrest due to ventricular fibrillation (VF), appropriate implantable cardioverter defibrillator (ICD) interventions, or ICD therapy on fast VT/VF to guide ICD implantation is based on observational data and expert consensus. In this document, we review risk factors for SCD and indications for ICD implantation and additional therapies. What emerges is that, allowing for some important differences between cardiomyopathies and channelopathies, there is a growing and disquieting trend to create, and then use, semi-automated systems (risk scores, risk calculators, and, to some extent, even guidelines) which then dictate therapeutic choices. Their common denominator is a tendency to favour ICD implantation, sometime with reason, sometime without it. This contrasts with the time-honoured approach of selecting, among the available therapies, the best option (ICDs included) based on the clinical judgement for the specific patient and after having assessed the protection provided by optimal medical treatment.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Corrado D, Link MS, Schwartz PJ, et al. Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice? Eur Heart J. 2022. PMID: 35725934. doi:10.1093/eurheartj/ehac298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。